NetworkNewsWire
Editorial Coverage: As more Canadians than ever suffer chronic
pain, the chase is on to find novel therapeutic approaches to
effectively manage their conditions. In fact, BMC Public Health
estimates that 20% of adults on a global level suffer from chronic
pain while 10% are newly diagnosed every year. In Canada, chronic
pain affects 1.5 million people. As national and worldwide numbers
in pain diagnoses continue to rise, innovators in the cannabis
industry are developing promising therapies to address this growing
market. InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB:
IMLFF) (IMLFF
Profile), Aurora Cannabis, Inc. (OTCQX: ACBFF) (TSX:
ACB), Canopy Growth Corp. (OTC: TWMJF) (TSX:
WEED), Aphria, Inc. (OTCQB: APHQF) (TSX:
APH) and Isodiol International, Inc. (OTCQB:
ISOLF) (ISOL: CNX) each play a unique role in the
increased acceptance and promise of medical marijuana and its
purified derivatives for pain management and other medical
needs.
The medical cannabis industry in Canada alone has gained
impressive traction since its legalization in 2001, and industry
statistics show increases from CAD$49 million in 2015 to
projections of over $1.1 billion by the year 2020. Scientists,
doctors, and pharmaceutical companies alike attribute this
never-before seen rise in the market to consumer confidence in the
therapeutic qualities of cannabis-derived products.
As consumer acceptance continues to propel demand to
unprecedented levels, companies such as InMed
Pharmaceuticals (CSE: IN) (OTCQB: IMLFF) are making
waves in the advancement of cannabinoid compounds as a medical
solution in pain management and other indications. The
biopharmaceutical company focuses its efforts in the development of
novel therapies surrounding the extensive pharmacology of
cannabinoids (cannabis’ bioactive compounds) and innovative drug
delivery systems.
Canadian marijuana companies are leading the way on a global
scale by establishing high standards in the growing and cultivation
of quality products. InMed is taking a very unique approach by
focusing on a proprietary cannabinoid manufacturing process that
sets it apart as a catalyst of improvement in the availability of
pharmaceutical-grade cannabinoids.
The company’s proprietary biosynthesis process has the ability
to combine the intrinsic safety and efficacy of natural drug
structures with the convenience, control and quality of a
laboratory-based manufacturing process. Aside from significant cost
savings, this process enables enhanced production, purification,
and quality control compared to the typical
grow-harvest-extract-purify methods employed by other companies.
Notably, InMed’s biosynthesis system allows the manufacturing of
all of the 90+ naturally occurring cannabinoids at a relatively low
cost, regardless of how rare each compound may be in nature.
Using its exclusive process in a controlled laboratory setting,
InMed can manufacture cannabinoid compounds that are identical to
those found in nature without the difficult, expensive and
time-consuming challenges of planting, growing and harvesting
cannabis then laboriously extracting the individual cannabinoids
for medical use. It also completely eliminates any need for
fertilizers or pesticides.
Earlier this year, InMed Pharmaceutical filed a provisional U.S.
patent for its pain management program (http://nnw.fm/6GHOq). The program, which includes the
INM-405 therapy, along with other similar compositions of
cannabinoid-based topical therapies for the treatment of pain, is
an important step to not only protecting the company’s commercial
and intellectual property, but also in establishing themselves as a
major player in the pain management industry.
While there are numerous pharmaceutical products to treat both
acute and chronic pain, the increase in the number of prescriptions
for opioids has led to concerns of addiction, damaging side
effects, and death. According to the U.S. Centers for Disease
Control and Prevention, drug overdose deaths continue to increase
in the United States, with the majority (more than 60%) involving
an opioid. Since 1999, the number of overdose deaths involving
opioids (including prescription opioids and heroin) quadrupled, as
have the number of prescriptions for opioids, yet there has been no
increase in the amount of pain reported in the general population.
Thus, there is a need to find alternatives to treat chronic and
severe pain that are non-addictive and have limited side effects.
InMed is researching the potential of non-THC
(tetrahydrocannabinol, a psychoactive ingredient in cannabis)
cannabinoids to treat pain using a proprietary topical
formulation.
InMed’s advancements can be attributed to the company’s
proprietary bioinformatics assessment tool, which is able to
identify which cannabinoids can potentially target individual
diseases (including pain).
As Canada’s medical marijuana industry continues to grow at a
rapid rate, licensed producers of medical cannabis crops and
pharmaceutical-grade cannabinoids are placing special emphasis on
areas such as consistency and efficiency in order to keep up with
market demands and provide easier product access, especially
surrounding treatable conditions like pain management.
Aurora Cannabis (OTCQX: ACBFF) (TSX: ACB),
award-winning contributor to Canada’s legal medical cannabis
industry, provides top-quality cannabis to patients through
laboratory tested products, culture-minded cultivators, and a
network of highly educated doctors in the cannabis industry. It is
with these quality processes that they help to remove barriers of
access.
Every patient’s symptoms and situation is completely unique, and
so should be the care they receive. Aphria (OTCQB: APHQF)
(TSX: APH), a producer of high-quality, pure and safe
cannabis, combines superior patient care with products that are
safe and consistent, with a commitment to exceeding baseline
government and regulatory body standards for medical cannabis
products. When it comes to medicine, adequate is simply not good
enough. Aphria’s priorities lie within consistency, safety and
efficacy.
Others, such as Canopy Growth (OTC: TWMJF) (TSX:
WEED), is leading the world as a diversified cannabis
company through its partnerships with leading names in the sector.
The company’s core brands - Tweed, Spectrum Cannabis and Bedrocan
Canada - don’t just sell quality cannabis and create meaningful
customer relationships, they facilitate trusted conversations
surrounding cannabis, simplify stakeholder outreaches, healthcare
interactions, and patient education through color-identifying
spectrum labeling, as well as a commitment to research, refinement,
and licensing of medicinal cannabis products.
Companies such as Isodiol International (OTCQB: ISOLF)
(ISOL: CNX) take their research and development a step
further, focusing on the phytoceutical optimization of cannabinoids
to maximize the bioactivity in the human body, allowing a more
targeted treatment of specific health conditions. As an industry
leader in the development and manufacturing of consumer products
and raw ingredients derived from cannabis, Isodiol has pioneered
many of the first hemp derivatives including micro-encapsulation
for topical products, a 99% pure crystalline power, and
nanotechnology for use in beverage and food applications.
Indeed, the overall support for medical cannabis appears to be
on the rise, with an overwhelming amount of reports revealing high
success in pain reduction as well as the reduction of other
medication needs in the presence of medical marijuana and
cannabinoid use. InMed Pharmaceuticals appears to be tackling these
breakthroughs in conventional medication with its own
scientifically derived advancements in the biosynthesis process.
These advancements present a unique opportunity for those
interested in investing in the rapid pace of the cannabinoid
pharmaceutical and pain management industries.
For more information on InMed Pharmaceuticals, visit InMed
Pharmaceuticals, Inc. (OTCQB: IMLFF) (CSE: IN)
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides
(1) access to our news aggregation and syndication servers, (2)
NetworkNewsBreaks that summarize corporate news and
information, (3) enhanced press release services, (4) social media
distribution and optimization services, and (5) a full array of
corporate communication solutions. As a multifaceted financial news
and content distribution company with an extensive team of
contributing journalists and writers, NNW is uniquely positioned to
best serve private and public companies that desire to reach a wide
audience of investors, consumers, journalists and the general
public. NNW has an ever-growing distribution network of more than
5,000 key syndication outlets across the country. By cutting
through the overload of information in today’s market, NNW brings
its clients unparalleled visibility, recognition and brand
awareness. NNW is where news, content and information converge.
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article
and content set forth above. References to any issuer other than
the profiled issuer are intended solely to identify industry
participants and do not constitute an endorsement of any issuer and
do not constitute a comparison to the profiled issuer. The
commentary, views and opinions expressed in this release by NNW are
solely those of NNW. Readers of this Article and content agree that
they cannot and will not seek to hold liable NNW for any investment
decisions by their readers or subscribers. NNW are a news
dissemination and financial marketing solutions provider and are
NOT registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy
any security.
The Article and content related to the profiled company
represent the personal and subjective views of the Author, and are
subject to change at any time without notice. The information
provided in the Article and the content has been obtained from
sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all
such information. None of the Author, NNW, or any of their
respective affiliates, guarantee the accuracy or completeness of
any such information. This Article and content are not, and should
not be regarded as investment advice or as a recommendation
regarding any particular security or course of action; readers are
strongly urged to speak with their own investment advisor and
review all of the profiled issuer’s filings made with the
Securities and Exchange Commission before making any investment
decisions and should understand the risks associated with an
investment in the profiled issuer’s securities, including, but not
limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. “Forward-looking statements” describe future expectations,
plans, results, or strategies and are generally preceded by words
such as “may”, “future”, “plan” or “planned”, “will” or “should”,
“expected,” “anticipates”, “draft”, “eventually” or “projected”.
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company’s annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and NNW undertake no
obligation to update such statements.
Source:
NetworkNewsWire
Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Isodiol (CSE:ISOL)
過去 株価チャート
から 11 2024 まで 12 2024
Isodiol (CSE:ISOL)
過去 株価チャート
から 12 2023 まで 12 2024
